The retinoid x receptor agonist bexarotene relieves positive symptoms of schizophrenia: A 6-week, randomized, double-blind, placebo-controlled multicenter trial

Journal of Clinical Psychiatry

Volumn 74, Issue 12, 2013, Pages 1224-1232

  Lerner, Vladimir ^a   Miodownik, Chanoch ^a   Gibel, Anatoly ^b   Sirota, Pinchas ^c   Bush, Ilan ^a   Elliot, Hadi ^c   Benatov, Ruben ^c   Ritsner, Michael S ^b,d  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b SHA'AR MENASHE MENTAL HEALTH CENTER   (Israel)

^c ABARBANEL MENTAL HEALTH CENTER   (Israel)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; BENZODIAZEPINE DERIVATIVE; BEXAROTENE; BEZAFIBRATE; CARBAMAZEPINE; CHLORPROMAZINE; CHOLESTEROL; CLOZAPINE; HALOPERIDOL; LAMOTRIGINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RETINOID X RECEPTOR; RISPERIDONE; SIMVASTATIN; THYROXINE; VALPROIC ACID; ZIPRASIDONE; ZUCLOPENTHIXOL;

ADD ON THERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; DSM-IV-TR; EFFECT SIZE; FEMALE; FUNCTIONAL STATUS; HOSPITAL PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; OUTPATIENT; PATIENT SELECTION; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; THYROID DISEASE; TREATMENT DURATION; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE-BLIND METHOD; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; QUALITY OF LIFE; RETINOID X RECEPTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TETRAHYDRONAPHTHALENES; TREATMENT OUTCOME;

EID: 84891455454     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.12m08160     Document Type: Article

References (61)

1. Gniadecki R, Assaf C, Bagot M, et al. The optimal use of bexarotene in cutaneous T-cell lymphoma. Br J Dermatol. 2007;157(3):433-440.
2. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J. 1996;10(9):940-954.
3. Germain P, Chambon P, Eichele G, et al. International Union of Pharmacology. LXIII: retinoid X receptors. Pharmacol Rev. 2006;58(4):760-772.
4. Mangelsdorf DJ, Umesomo K, Evans RM. The retinoid receptors. In: Sporn MB, Roberts AB, Goodman DWS, eds. The Retinoids: Biology, Chemistry, and Medicine. 2nd ed. New York, NY: Raven Press; 1994:319-350.
5. Farol LT, Hymes KB. Bexarotene: a clinical review. Expert Rev Anticancer Ther. 2004;4(2):180-188.
6. Qu L, Tang X. Bexarotene: a promising anticancer agent. Cancer Chemother Pharmacol. 2010;65(2):201-205.
7. Pinaire JA, Reifel-Miller A. Therapeutic potential of retinoid x receptor modulators for the treatment of the metabolic syndrome. PPAR Res. 2007;2007:94156.
8. Janssen JS, Sharma V, Pugazhenthi U, et al. A rexinoid antagonist increases the hypothalamic-pituitary-thyroid set point in mice and thyrotrope cells. Mol Cell Endocrinol. 2011;339(1-2):1-6.
9. Esteva FJ, Glaspy J, Baidas S, et al. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol. 2003;21(6):999-1006.
10. Hurst RE. Bexarotene ligand pharmaceuticals. Curr Opin Investig Drugs. 2000;1(4):514-523.
11. Lerner V, Miodownik C, Gibel A, et al. Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: a pilot open-label trial. Clin Neuropharmacol. 2008;31(1):25-33.
12. Cramer PE, Cirrito JR, Wesson DW, et al. ApoE-directed therapeutics rapidly clear ?-amyloid and reverse deficits in AD mouse models. Science. 2012;335(6075):1503-1506.
13. Goodman AB. Three independent lines of evidence suggest retinoids as causal to schizophrenia. Proc Natl Acad Sci U S A. 1998;95(13):7240-7244.
14. Goodman AB. Microarray results suggest altered transport and lowered synthesis of retinoic acid in schizophrenia. Mol Psychiatry. 2005;10(7): 620-621.
15. Lane MA, Bailey SJ. Role of retinoid signalling in the adult brain. Prog Neurobiol. 2005;75(4):275-293.
16. McCaffery P, Zhang J, Crandall JE. Retinoic acid signaling and function in the adult hippocampus. J Neurobiol. 2006;66(7):780-791.
17. Palha JA, Goodman AB. Thyroid hormones and retinoids: a possible link between genes and environment in schizophrenia. Brain Res Brain Res Rev. 2006;51(1):61?71. doi:10.1016/j.brainresrev.205.10.01 PubMed
18. Rioux L, Arnold SE. The expression of retinoic acid receptor alpha is increased in the granule cells of the dentate gyrus in schizophrenia. Psychiatry Res. 2005;133(1):13-21.
19. Smith JE, Milch PO, Muto Y, et al. The plasma transport and metabolism of retinoic acid in the rat. Biochem J. 1973;132(4):821-827.
20. Wan C, Yang Y, Li H, et al. Dysregulation of retinoid transporters expression in body fluids of schizophrenia patients. J Proteome Res. 2006;5(11): 3213-3216.
21. Livera G, Pairault C, Lambrot R, et al. Retinoid-sensitive steps in steroidogenesis in fetal and neonatal rat testes: in vitro and in vivo studies. Biol Reprod. 2004;70(6):1814-1821.
22. Ritsner MS, Gibel A, Ratner Y, et al. Dehydroepiandrosterone and pregnenolone alterations in schizophrenia. In: Weizman A, ed. Neuroactive Steroids in Brain Functions, and Mental Health New Perspectives for Research and Treatment. New York, NY: Springer Springer-Verlag; 2008:251-298.
23. Lengqvist J, Mata De Urquiza A, Bergman AC, et al. Polyunsaturated fatty acids including docosahexaenoic and arachidonic acid bind to the retinoid X receptor alpha ligand-binding domain. Mol Cell Proteomics. 2004;3(7): 692-703.
24. Goodman AB. Congenital anomalies in relatives of schizophrenic probands may indicate a retinoid pathology. Schizophr Res. 1996;19(2-3):163-170.
25. Carfagno ML, Hoskins LA, Pinto ME, et al. Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: II. Glutamate(Ant)agonists. Ann Pharmacother. 2000;34(6):788-797.
26. Dixon DA, Fenix LA, Kim DM, et al. Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: I. Adenosine agonists. Ann Pharmacother. 1999;33(4):480-488.
27. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
28. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. US Department of Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976:534-537.
29. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261?276. doi:10.1093/schbul/13.2.261 PubMed
30. Bischoff ED, Heyman RA, Lamph WW. Effect of the retinoid X receptorselective ligand LGD1069 on mammary carcinoma after tamoxifen failure. J Natl Cancer Inst. 1999;91(24):2118.
31. Khuri FR, Rigas JR, Figlin RA, et al. Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2001;19(10):2626-2637.
32. Lehman AF, Lieberman JA, Dixon LB, et al; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(suppl):1-56.
33. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64(6):663-667.
34. White L, Harvey PD, Opler L, et al; The PANSS Study Group. Empirical assessment of the factorial structure of clinical symptoms in schizophrenia: a multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. Psychopathology. 1997;30(5):263-274.
35. Ritsner M, Kurs R, Gibel A, et al. Validity of an abbreviated quality of life enjoyment and satisfaction questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective, and mood disorder patients. Qual Life Res. 2005;14(7): 1693-1703.
36. Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res. 2005;76(2-3):247-265
37. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154(5):672-676.
38. SAS Institute Inc. SAS/STAT 9.2 User?s Guide. Cary, NC: SAS Institute Inc; 2008.
39. Hintze JL. NCSS-2007. Statistical System for Windows. User?s Guide. Kaysville, Utah: Number Cruncher Statistical Systems; 2006.
40. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38(4):963-974.
41. Hamer RM, Simpson PM. Last observation carried forward versus mixed models in the analysis of psychiatric clinical trials. Am J Psychiatry. 2009;166(6):639-641.
42. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Earlbaum Associates; 1988.
43. Khin NA, Chen YF, Yang Y, et al. Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration. J Clin Psychiatry. 2012;73(6):856-864.
44. de Vries-van der Weij J, de Haan W, Hu L, et al. Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein. Endocrinology. 2009;150(5):2368-2375.
45. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(suppl 1):1-93.
46. Rettenbacher MA. Disturbances of glucose and lipid metabolism during treatment with new generation antipsychotics. Curr Opin Psychiatry. 2005;18(2):175-179.
47. Rettenbacher MA, Ebenbichler C, Hofer A, et al. Early changes of plasma lipids during treatment with atypical antipsychotics. Int Clin Psychopharmacol. 2006;21(6):369-372.
48. Bailey SJ, McCaffery PJ. Retinoic acid signaling in neuropsychiatric disease: possible markers and treatment agents. In: Ritsner MS, ed. The Handbook of Neuropsychiatric Biomarkers, Endophenotypes, and GenesVolume III: Metabolic and Peripheral Biomarkers. Dordrecht, Netherlands: Springer Netherlands; 2009:171-189.
49. Smit JW, Stokkel MP, Pereira AM, et al. Bexarotene-induced hypothyroidism: bexarotene stimulates the peripheral metabolism of thyroid hormones. J Clin Endocrinol Metab. 2007;92(7):2496-2499.
50. Sherman SI. Etiology, diagnosis, and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma. Clin Lymphoma. 2003;3(4):249-252.
51. Aoto J, Nam CI, Poon MM, et al. Synaptic signaling by all-trans retinoic acid in homeostatic synaptic plasticity. Neuron. 2008;60(2):308-320.
52. Maghsoodi B, Poon MM, Nam CI, et al. Retinoic acid regulates RARalphamediated control of translation in dendritic RNA granules during homeostatic synaptic plasticity. Proc Natl Acad Sci U S A. 2008;105(41):16015- 16020.
53. Misner DL, Jacobs S, Shimizu Y, et al. Vitamin A deprivation results in reversible loss of hippocampal long-term synaptic plasticity. Proc Natl Acad Sci U S A. 2001;98(20):11714-11719.
54. Chiang MY, Misner D, Kempermann G, et al. An essential role for retinoid receptors RARbeta and RXRgamma in long-term potentiation and depression. Neuron. 1998;21(6):1353-1361.
55. Nomoto M, Takeda Y, Uchida S, et al. Dysfunction of the RAR/RXR signaling pathway in the forebrain impairs hippocampal memory and synaptic plasticity. Mol Brain. 2012;5(1):8.
56. Sato Y, Meller R, Yang T, et al. Stereo-selective neuroprotection against stroke with vitamin A derivatives. Brain Res. 2008;1241:188-192.
57. Samad TA, Krezel W, Chambon P, et al. Regulation of dopaminergic pathways by retinoids: activation of the D2 receptor promoter by members of the retinoic acid receptor-retinoid X receptor family. Proc Natl Acad Sci U S A. 1997;94(26):14349-14354.
58. Davis KL, Kahn RS, Ko G, et al. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991;148(11):1474-1486.
59. Kwok SK, Park MK, Cho ML, et al. Retinoic acid attenuates rheumatoid inflammation in mice. J Immunol. 2012;189(2):1062-1071.
60. Mucida D, Park Y, Kim G, et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science. 2007;317(5835):256-260.
61. Muller N, Myint AM, Schwarz MJ. Inflammation in schizophrenia. Adv Protein Chem Struct Biol. 2012;88:49-68.